RE: today's action = Smith+Nephew CCNote the targetting of the acticoat opportunity in their press release:
Globally, we have refocused our sales forces on the market opportunities for ALLEVYN(+) hydrocellular dressings and ACTICOAT(+) antimicrobial silver dressings. We have seen the benefits of this in the sales of ALLEVYN(+) which grew by 17% and ACTICOAT(+) which grew by 42%. In the US, we have also implemented a targeted approach to DERMAGRAFT(+) tissue engineered dermal replacement which grew by 21%.
https://biz.yahoo.com/iw/050203/080285.html